The other actionable mutation found in NSCLC is a translocation in echinoderm microtubule associated protein-like 4 – anaplastic lymphoma kinase (EML4–ALK) gene, which is found in approximately 4% of patients with adenocarcinoma (75). This evidence concerns the gene ALK and non-small cell lung carcinoma.